second week of tirzepatide What to expect after your first dose tirzepatide: the complete hour-by-hour guide Tirzepatide on ingestive behavior in

Ozempic as an add-on to basal insulin and Ozempic 1 mg vs 2 mg SUSTAIN 5: add-on basal insulin 1,10 In patients with type 2 diabetes on basal insulin metformin Secondary endpoint: mean change in body weight from baseline to Week 30 Mean baseline: 202 lb SUSTAIN FORTE: Ozempic 1 mg vs 2 mg 1,4,8 In patients with type 2 diabetes on metformin sulfonylurea Secondary endpoint: mean change in body weight from baseline to Week 40 Mean baseline: 219 lb Results based on sensitivity analyses of retrieved dropout population

Providing a treatment option that is proven to lower this cardiovascular risk is a major advance for public health. Wegovy was first cleared for obesity in adults in 2021 and had its label extended in 2022 to include adolescents aged 12 and over

Maintain adequate nutrition despite reduced appetite

Achievable plans for lasting outcomes By design, the program encourages long-lasting changes to health behaviors Achieving program goals drives better outcomes for your population Delivered as a key preventive health offering within your benefits ecosystem, or part of your daily use, personalized health platform to maximize ongoing support Financial benefits & outcomes you can count on 3:1 VOI Embedded within your personalized, daily use health, wellbeing, and navigation solution 99% Satisfaction Among participants who also improved their weight, activity, and mental wellbeing Better outcomes Transform outperforms similar programs' weight loss avg by 49%

The advantages of each, as well as when they might be most useful in your daily routine